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Abstract
Cisplatin (CDDP) is a platinum complex and is used for treatment of solid tumors. CDDP administered 
intravenously is ingested into the cels by copper transporter 1 (CTR1). Silver sulfadiazine (AgSD) is a 
topical antibiotic that prevent wound infection. Ag is reported to inhibit the mechanism of CTR1. We 
examined transporter-mediated drug-drug interaction using CDDP and AgSD in rats. The serum 
concentrations of platinum in blood and in kidney and liver tissues were measured. A blood test was 
performed to observe the interactive efects of CDDP and AgSD. AgSD pretreatment significantly 
decreased the concentrations of platinum in blood and in kidney tissue compared to the control. AgSD also 
diminished the CDDP-induced abnormalities of serum creatinine level but did not afect CTR1 expression. 
In contrast, no significant change was observed in platinum concentration in liver tissue after AgSD 
pretreatment. However, the level of alanine aminotransferase increased after administration of CDDP 
with or without AgSD. These results suggest that CDDP administered intravenously interacts with AgSD 
applied to region of wound, in association with changing the platinum concentrations in blood and tissue 
distribution. The interactive efects of CDDP may relate to modulate the function of platinum transferring 
via CTR1 in the presence of Ag.
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濃 度 の 測 定 を 行 っ た．SCr濃 度 はQuantiChromTM 
















測定した．抗体は，Anti CTR⚑ Rabbit-poly antibody
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